| 發表論文 | Peer-Reviewed Original Research Articles
- Yap WK, Lin CH, Hsu KH, Chen PY, Lin CY, Lin SN,
Cheng NM, Chang KP, Kang CJ, Young CK, Liau CT, Lu YA, Hu YF, Yeh CC, Yeh TS,
Tsai TY. Pretreatment nodal SUVmax predicts neck progression in hypopharyngeal
cancer undergoing definitive chemoradiotherapy, while higher radiotherapy dose
improves regional control particularly in the high SUV-N subgroup: a long-term
outcome study. Am J Cancer Res. 2026;16(1):240??54.
- Yap WK#, Cheng SC#, Lin CH, Hsiao IT, Tsai
TY, Yap WL, Chen WP, Lin CY, Huang SM. An External Validation Study on Two
Pre-Trained Large Language Models for Multimodal Prognostication in Laryngeal
and Hypopharyngeal Cancer: Integrating Clinical, Treatment, and Radiomic Data
to Predict Survival Outcomes with Interpretable Reasoning. Bioengineering
(Basel). 2025 Dec 10;12(12):1345. doi: 10.3390/bioengineering12121345. PMID:
41463641; PMCID: PMC12729448.
- Luan CW, Tsai YT, Chen
KY, Yap WK*. Prognostic
significance of estimated radiation dose to immune cells in cancer patients
undergoing thoracic irradiation: A meta-analysis. Radiother Oncol. 2025
Nov;212:111123. doi: 10.1016/j.radonc.2025.111123. Epub 2025 Sep 6.
- Yap WK, Lin CH, Hsu KH, Lin SN, Lin HC, Chang KP,
Kang CJ, Hu YF, Shih MC, Tsai TY. Prognostic Value and Clinical Implication of
Lymph Node-to-Primary Tumor SUV Ratio in Node-Positive Hypopharyngeal Squamous
Cell Carcinoma Treated With Radiotherapy With or Without Chemotherapy. Clin
Nucl Med. 2025 Jan 1;50(1):11-18. doi: 10.1097/RLU.0000000000005544. Epub 2024
Oct 17. PMID: 39441098
- Tsai TY#, Yap WK#, Wang TH, Lu YA, See
A, Hu YF, Huang Y, Kao HK, Chang KP. Upfront Surgery Versus Upfront Concurrent
Chemoradiotherapy as Primary Modality in Hypopharyngeal Squamous Cell
Carcinoma: A Systematic Review and Meta-Analysis. J Otolaryngol Head Neck Surg.
2024 Jan-Dec;53:19160216241293633. doi: 10.1177/19160216241293633. PMID:
39468833; PMCID: PMC11528607.
- Yap WK#, Hsu KH#, Wang TH, Lin CH, Kang
CJ, Huang SM, Lin HC, Hung TM, Chang KP, Tsai TY. The prognostic value of lymph
node to primary tumor standardized uptake value ratio in cancer patients: a
meta-analysis. Ann Nucl Med. 2024 Aug;38(8):607-618. doi: 10.1007/s12149-024-01933-5.
Epub 2024 May 9. PMID: 38724805.
- Tsai TY, Chiang PC, Yap WK,
Huang Y, See A, Hung SY, Lu CY, Lin CY, Chang TJ, Kao HK, Chang KP.
Postoperative radiotherapy versus surgery alone in pN1 oral cavity cancer
patients: A meta-analysis. Laryngoscope Investig Otolaryngol. 2024 May
15;9(3):e1260. doi: 10.1002/lio2.1260. PMID: 38751691; PMCID: PMC11094775.
- Lin CH, Yan JL, Yap WK,
Kang CJ, Chang YC, Tsai TY, Chang KP, Liao CT, Hsu CL, Chou WC, Wang HM, Huang
PW, Fan KH, Huang BS, Tung-Chieh Chang J, Tu SJ, Lin CY. Prognostic value of
interim CT-based peritumoral and intratumoral radiomics in laryngeal and
hypopharyngeal cancer patients undergoing definitive radiotherapy. Radiother
Oncol. 2023 Dec;189:109938. doi: 10.1016/j.radonc.2023.109938. Epub 2023 Oct 6.
PMID: 37806562.
- Yap WK, Hsiao IT, Yap WL, Tsai TY, Lu YA, Yang CK, Peng
MT, Su EL, Cheng SC. A Radiotherapy Dose Map-Guided Deep Learning Method for
Predicting Pathological Complete Response in Esophageal Cancer Patients after
Neoadjuvant Chemoradiotherapy Followed by Surgery. Biomedicines. 2023 Nov
16;11(11):3072. doi: 10.3390/biomedicines11113072. PMID: 38002072; PMCID:
PMC10669191.
- Chou HD, Yap WK, Wang CC, Chao AN. Clinical
outcomes of fiducial-free proton beam therapy in Asian patients with uveal
melanoma. Clin Exp Ophthalmol. 2023 Nov;51(8):875-878. doi: 10.1111/ceo.14299.
Epub 2023 Sep 24. PMID: 37743703.
- Wu TH, Tsai YT, Chen KY, Yap WK*,
Luan CW*. Utility of High-Sensitivity Modified Glasgow Prognostic Score in
Cancer Prognosis: A Systemic Review and Meta-Analysis. Int J Mol Sci. 2023 Jan
10;24(2):1318. doi: 10.3390/ijms24021318. PMID: 36674837; PMCID: PMC9866297.
- Yap WK, Shih MC, Chang YC, Lin CH, Huang SM, Tsai TY,
Chang CF, Hsu CC, Tseng CK, Chen MF, Tsan DL, Liau CT, Hou MM, Chao YK, Chiu
CH, Hung TM. Adjuvant Chemoradiotherapy Associated with Improved Overall
Survival in Resected Esophageal Squamous Cell Carcinoma after Neoadjuvant
Chemoradiotherapy in Intensity-Modulated Radiotherapy Era. Biomedicines. 2022
Nov 21;10(11):2989. doi: 10.3390/biomedicines10112989. PMID: 36428557; PMCID:
PMC9687609.
- Chiang YY, Chou YC, Chang KP, Liao CT, Wu YY, Yap WK, Pai PC, Chang JT, Lin CY, Fan KH, Huang BS, Hung TM,
Tsang NM. Missed radiation therapy sessions in first three weeks predict
distant metastasis and less favorable outcomes in surgically treated patients
with oral cavity squamous cell carcinoma. Radiat Oncol. 2020 Aug 14;15(1):194.
doi: 10.1186/s13014-020-01632-1. PMID: 32795324; PMCID: PMC7427928.
- Lin YH, Huang SM, Yap WK,
Yang JW, Yeung L, Tsan DL, Chang JT, Chen LC. Outcomes in patients with
lacrimal gland carcinoma treated with definitive radiotherapy or eye-sparing
surgery followed by adjuvant radiotherapy. Radiat Oncol. 2020 Jun 22;15(1):156.
doi: 10.1186/s13014-020-01601-8. PMID: 32571366; PMCID: PMC7310012.
- Chen PJ, Yap WK, Chang YC,
Tseng CK, Chao YK, Hsieh JC, Pai PC, Lee CH, Yang CK, Ho AT, Hung TM.
Prognostic value of lymph node to primary tumor standardized uptake value ratio
in unresectable esophageal cancer. BMC Cancer. 2020 Jun 10;20(1):545. doi:
10.1186/s12885-020-07044-4. PMID: 32522275; PMCID: PMC7288503.
- Lin CH, Hung TM, Chang YC, Hsieh CH, Shih MC, Huang SM, Yang CK, Chang
CF, Chan SC, Yap WK*. Prognostic
Value of Lymph Node-To-Primary Tumor Standardized Uptake Value Ratio in
Esophageal Squamous Cell Carcinoma Treated with Definitive Chemoradiotherapy.
Cancers (Basel). 2020 Mar 6;12(3):607. doi: 10.3390/cancers12030607. PMID:
32155748; PMCID: PMC7139766.
- Huang SM, Chen YC, Chen WY, Yang LY, Tsan DL, Tsang NM, Yap WK, Tsai CS, Leung WM, Hong JH,
Chang JT, Yeh TS, Wu TH, Chen YC, Lin YH, Huang BS. Optimal Timing for
Postsurgical Adjuvant Therapy in Patients with Gastric Cancer: A Propensity
Score Matching Study. J Cancer. 2019 Jan 1;10(2):332-340. doi: 10.7150/jca.27753.
PMID: 30719127; PMCID: PMC6360315.
- Yap WK, Shih MC, Kuo C, Pai PC, Chou WC, Chang KP, Tsai
MH, Tsang NM. Development and Validation of a Nomogram for Assessing Survival
in Patients With Metastatic Lung Cancer Referred for Radiotherapy for Bone
Metastases. JAMA Netw Open. 2018 Oct 5;1(6):e183242. doi:
10.1001/jamanetworkopen.2018.3242. PMID: 30646236; PMCID: PMC6324455.
- Yap WK, Chang YC, Hsieh CH, Chao YK, Chen CC, Shih MC,
Hung TM. Favorable versus unfavorable prognostic groups by post-chemoradiation
FDG-PET imaging in node-positive esophageal squamous cell carcinoma patients
treated with definitive chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2018
May;45(5):689-698. doi: 10.1007/s00259-017-3901-3. Epub 2017 Nov 30. PMID:
29188300.
- Yap WK, Chang YC, Tseng CK, Hsieh CH, Chao YK, Su PJ, Hou
MM, Yang CK, Pai PC, Lin CR, Hsieh CE, Wu YY, Hung TM. Predictive value of
nodal maximum standardized uptake value of pretreatment [18F]fluorodeoxyglucose
positron emission tomography imaging in patients with esophageal cancer. Dis
Esophagus. 2017 Aug 1;30(8):1-10. doi: 10.1093/dote/dox021. PMID: 28575243.
Oral Presentations at International Conferences
- Taiwan Joint Cancer Conference 2016
- The 6th Japan-Taiwan Radiation Oncology Symposium 2018
Poster Presentations at International Conferences
- Taiwan Joint Cancer Conference 2016
- American Society for Radiation Oncology (ASTRO) meeting 2016, at Boston, USA
- Taiwan Joint Cancer Conference 2017
- The 5th Japan-Taiwan Radiation Oncology Symposium 2017, at Kobe, Japan.
- European Society for Radiotherapy & Oncology (ESTRO) Conference 2018, at Barcelona, Spain.
- The 6th Japan-Taiwan Radiation Oncology Symposium 2018
- American Society for Radiation Oncology (ASTRO) meeting 2018, at San Antonio, USA
|